Profiling the Tox21 Compound Library for Their Inhibitory Effects on Cytochrome P450 Enzymes
Authors:
- Srilatha SakamuruSSSrilatha Sakamuru
- Jameson TraversJTJameson Travers
- Carleen Klumpp-ThomasCKCarleen Klumpp-Thomas
- Ruili HuangRHRuili Huang
- Kristine L. WittKWKristine L. Witt
- Stephen S. FergusonSFStephen S. Ferguson
- Steven O. SimmonsSSSteven O. Simmons
- David M. ReifDavid M. Reif
- Anton SimeonovASAnton Simeonov
- Menghang XiaMXMenghang Xia
Open Access
- 22 May 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 4976
Abstract
Cytochrome P450 (CYP) enzymes are membrane-bound hemoproteins crucial for drug and xenobiotic metabolism. While more than 50 CYPs have been identified in humans, the isoforms from CYP1, 2, and 3 families contribute to the metabolism of about 80% of clinically approved drugs. To evaluate the effects of environmental chemicals on the activities of these important CYP enzyme families, we screened the Tox21 10K compound library to identify chemicals that inhibit CYP1A2, 2C9, 2C19, 2D6, and 3A4 enzymes. The data obtained from these five screenings were analyzed to reveal the structural classes responsible for inhibiting multiple and/or selective CYPs. Some known structural compound classes exhibiting pan-CYP inhibition, such as azole fungicides, along with established clinical inhibitors of CYPs, including erythromycin and verapamil inhibiting CYP3A4 and paroxetine and terbinafine inhibiting CYP2D6, were all confirmed in the current study. In addition, some selective CYP inhibitors, previously unknown but with potent activity (IC50 values < 1 µM), were identified. Examples included yohimbine, an indole alkaloid, and loteprednol, a corticosteroid, which showed inhibitory activity in CYP2D6 and 3A4 assays, respectively. These findings suggest that assessment of a candidate compound’s impact on CYP function may allow pre-emptive mitigation of potential adverse reactions and toxicity during drug development or toxicological characterization of environmental chemicals.Keywords
Funding Information
- Tox21 Cross Partner Project (#9, #NTR 12003)
- National Institute of Environmental Health Sciences (NIEHS)/Division of Translational Toxicology to the NCATS, National Institutes of Health (NIH) (#9, #NTR 12003)
This publication has 45 references indexed in Scilit:
- Development and validation of CYP26A1 inhibition assay for high‐throughput screeningBiotechnology Journal, 2024
- Use of Tox21 screening data to profile PFAS bioactivities on nuclear receptors, cellular stress pathways, and cytochrome p450 enzymesJournal of Hazardous Materials, 2024
- Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activationArchives of Toxicology, 2022
- Anthraquinones inhibit cytochromes P450 enzyme activity in silico and in vitroJournal of Applied Toxicology, 2021
- Inhibitory effects of polyphenols and their colonic metabolites on CYP2D6 enzyme using two different substratesBiomedicine & Pharmacotherapy, 2020
- Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular SurgeryClinical Drug Investigation, 2020
- Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current researchBioorganic & Medicinal Chemistry Letters, 2019
- Self-organizing neural projectionsNeural Networks, 2006
- Covalent Alteration of the CYP3A4 Active Site: Evidence for Multiple Substrate Binding DomainsArchives of Biochemistry and Biophysics, 2001
- The pharmacokinetics of yohimbine in manEuropean Journal of Clinical Pharmacology, 1987